Abstract

In mice, time of day strongly influences lethality in response to LPS, with survival greatest at the beginning compared to the end of the light cycle. Here we show that feeding, rather than light, controls time-of-day dependent LPS sensitivity. Mortality following LPS administration is independent of cytokine production and the clock regulator BMAL1 expressed in myeloid cells. In contrast, deletion of BMAL1 in hepatocytes globally disrupts the transcriptional response to the feeding cycle in the liver and results in constitutively high LPS sensitivity. Using RNAseq and functional validation studies we identify hepatic farnesoid X receptor (FXR) signalling as a BMAL1 and feeding-dependent regulator of LPS susceptibility. These results show that hepatocyte-intrinsic BMAL1 and FXR signalling integrate nutritional cues to regulate survival in response to innate immune stimuli. Understanding hepatic molecular programmes operational in response to these cues could identify novel pathways for targeting to enhance endotoxemia resistance.

Time of day influences immune responses and lethality in response to LPS, with survival greatest at the beginning compared to the end of the light cycle. Here the authors show that feeding, rather than light, controls time-of-day dependent LPS sensitivity through the liver clock and hepatic FXR signalling.

Details

Title
Feeding-induced resistance to acute lethal sepsis is dependent on hepatic BMAL1 and FXR signalling
Author
Geiger, Sarah S 1 ; Traba Javier 2 ; Richoz Nathan 3 ; Farley, Taylor K 3 ; Brooks, Stephen R 4 ; Petermann Franziska 5 ; Wang Lingdi 6 ; Gonzalez, Frank J 7   VIAFID ORCID Logo  ; Sack, Michael N 6 ; Siegel, Richard M 3 

 National Institutes of Health, Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165); Trinity College Dublin, Department of Biochemistry and Immunology, Trinity Biomedical Science Institute (TBSI), Dublin, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705) 
 National Institutes of Health, Laboratory of Mitochondrial Biology and Metabolism, National Heart Lung and Blood Institute (NHLBI), Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165); Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126) 
 National Institutes of Health, Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
 NIH, Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
 National Institutes of Health, Lymphocyte Cell Biology Section, Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
 National Institutes of Health, Laboratory of Mitochondrial Biology and Metabolism, National Heart Lung and Blood Institute (NHLBI), Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
 National Institutes of Health, Laboratory of Metabolism, National Cancer Institute (NCI), Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2525888922
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.